BTIG raised the firm’s price target on Guardant Health (GH) to $55 from $50 and keeps a Buy rating on the shares. The firm reiterated Guardant as a Top Pick, noting that the shares are up following news that the company obtained Medicare coverage for its Guardant Reveal MRD test for the first time in the surveillance monitoring setting, and the initial indication is for colorectal cancer. BTIG belives this is one of the biggest catalysts in the company’s history, and that the news takes positive sentiment to “a new level.” The firm believes the news adds upside to the numbers, though it plans to revisit its model next month.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health: MolDX administrator grants coverage for Guardant Reveal
- Guardant Health, ConcertAI team for RWD that integrates EMR data for cancer care
- Guardant Health Reports Revenue Growth Amid Cash Flow Losses
- Guardant Health reports preliminary Q4 revenue $200M, consensus $188.92M
- Guardant Health raises FY24 revenue view to $737M from $720M-$725M